Lilly Zyprexa Zydis

Orally disintegrating tablet formulation of olanzapine approved by FDA April 6. Lilly said it plans to manufacture the 5 mg and 10 mg doses of Zyprexa Zydis only, although it may later add 15 mg and 20 mg doses which were also approved. Approval was based on bioequivalence to Zyprexa tablets. The Zydis technology was developed by Cardinal's R.P. Scherer division